(Reuters) -Abbott Laboratories has agreed to discontinue sales of its Similac Probiotic Tri-Blend product used for hospitalized preterm infants after the U.S. Food and Drug Administration issued a warning letter to the company.
“The product is an unapproved new drug and an unlicensed biological product being sold in violation” of regulations, the health regulator said on Thursday.
(Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)
